Innate Pharma (IPHA) Debt Ratio (2017 - 2025)

Innate Pharma has reported Debt Ratio for 9 years, with the latest figure at 0.36 in Q4 2025.

• For the quarter ending Q4 2025, Debt Ratio rose 28.96% year-over-year to 0.36; the trailing twelve-month figure through Dec 2025 stood at 0.36 (up 28.96% YoY), and the FY2025 full-year result was 0.36, up 28.96% from the prior year.
• Debt Ratio for Q4 2025 stood at 0.36, up from 0.29 in the prior quarter.
• The five-year high for Debt Ratio was 0.36 in Q4 2025, with the low at 0.06 in Q2 2021.
• Historically, Debt Ratio has averaged 0.22 across 5 years, with a median of 0.22 in 2023.
• The largest YoY upside for Debt Ratio was 166.44% in 2021 against a maximum downside of 9.72% in 2021.
• Innate Pharma's Debt Ratio stood at 0.17 in 2021, then increased by 22.87% to 0.2 in 2022, then rose by 12.03% to 0.23 in 2023, then gained by 22.56% to 0.28 in 2024, then increased by 28.96% to 0.36 in 2025.
• The last three Debt Ratio figures came in at 0.36 (Q4 2025), 0.29 (Q2 2025), and 0.28 (Q4 2024), per Business Quant data.